LENZ Therapeutics (LENZ) Shares Outstanding (Weighted Average) (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $31.4 million in Q1 2026.

• Quarterly Shares Outstanding (Weighted Average) rose 13.9% year-over-year to $31.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.4 million (up 13.9% YoY) and the FY2025 annual result came in at $28.8 million, up 35.39% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $31.4 million in Q1 2026 per LENZ's latest filing, from $28.8 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $58.1 million in Q4 2022 and bottomed at $2.0 million in Q4 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $28.5 million (2025), against an average of $32.0 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) jumped 1138.78%; it then tumbled 96.63% in 2023.
• Tracing LENZ's Shares Outstanding (Weighted Average) over 5 years: stood at $58.1 million in 2022, then slumped by 96.63% to $2.0 million in 2023, then surged by 986.27% to $21.3 million in 2024, then soared by 35.39% to $28.8 million in 2025, then gained by 8.81% to $31.4 million in 2026.
• Per Business Quant, the three latest LENZ Shares Outstanding (Weighted Average) figures stand at $31.4 million (Q1 2026), $28.8 million (Q4 2025), and $28.5 million (Q3 2025).

Peer Comparison